{"id":"NCT01227824","sponsor":"ViiV Healthcare","briefTitle":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","officialTitle":"A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10-19","primaryCompletion":"2012-02-06","completion":"2016-12-27","firstPosted":"2010-10-25","resultsPosted":"2014-06-23","lastUpdate":"2018-10-09"},"enrollment":828,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Infection, Human Immunodeficiency Virus I"],"interventions":[{"type":"DRUG","name":"GSK1349572 (dolutegravir)","otherNames":[]},{"type":"DRUG","name":"raltegravir","otherNames":[]},{"type":"OTHER","name":"GSK1349572 Placebo","otherNames":[]},{"type":"OTHER","name":"ABC/3TC","otherNames":[]},{"type":"OTHER","name":"TDF/FTC","otherNames":[]},{"type":"OTHER","name":"raltegravir Placebo","otherNames":[]}],"arms":[{"label":"GSK1349572 (N=~394)","type":"EXPERIMENTAL"},{"label":"raltegravir (N=~394)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg once daily versus RAL 400mg twice daily over 48 weeks; non-inferiority will also be tested at Week 96. Both GSK1349572 and RAL will be given in combination with fixed-dose dual NRTI therapy (ABC/3TC or TDF/FTC). This study will be conducted in HIV-1 infected ART-na√Øve adult subjects.","primaryOutcome":{"measure":"Percentage of Participants With Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 Copies (c)/Milliliter (mL) Through Week 48","timeFrame":"Baseline up to Week 48","effectByArm":[{"arm":"DTG 50 mg Once a Day","deltaMin":88,"sd":null},{"arm":"RTG 400 mg BID","deltaMin":85,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":101,"countries":["United States","Australia","Canada","France","Germany","Italy","Russia","Spain","United Kingdom"]},"refs":{"pmids":["23306000","24074642"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":411},"commonTop":["Diarrhoea","Viral upper respiratory tract infection","Headache","Nausea","Upper respiratory tract infection"]}}